Key Highlights

● Class A shares began trading separately from the units on 10 April 2026.

● The offering reached 28,386,008 units and gross proceeds of about US$283.9 million.

● Quarterly net income was US$2,355,556, built from US$2,519,972 of trust interest.

● The deadline is 20 February 2028, extendable to 20 May 2028 with a definitive agreement.

Averin Capital Acquisition Corp. (NASDAQ:ACAA) is a Cayman Islands exempted blank check company, commonly called a special purpose acquisition company. Its Class A ordinary shares trade on the Nasdaq Global Market under the symbol ACAA. They began trading separately from the initial public offering units on 10 April 2026, according to the company's announcement of 8 April 2026. The latest quarterly report, for the period ended 30 June 2026, describes it as a shell company with no definitive agreement with any target, so no business combination has been announced. Each unit sold in the offering contained one Class A share and one-sixth of a warrant, so the ACAA line is the share component of those units.

How the offering was built

The prospectus, dated 18 February 2026, offered 25,000,000 units at US$10.00 each, with Deutsche Bank Securities as sole book-running manager. A press release of 5 March 2026 reported a partial exercise of the over-allotment option for 3,386,008 further units, taking the offering to 28,386,008 units and gross proceeds of about US$283.9 million. The sponsor also agreed to buy 200,000 private placement units. The quarterly report lists 28,586,008 Class A ordinary shares and 7,096,502 Class B ordinary shares outstanding at 5 August 2026.

What Class A holders can do

The prospectus says public shareholders may redeem their Class A shares for roughly US$10.00 each when a business combination completes, with redemptions by any shareholder or group capped at 15% of the offering shares. The company's trust account held US$287,367,170 at 30 June 2026, including roughly US$3.5 million of accumulated interest income. Redemption value per share therefore depends on the trust balance at the time, less any permitted withdrawals.

The Class B founder shares sit alongside the public shares. That structure is typical for such vehicles and means public shareholders absorb dilution when a deal closes.

Latest reported figures

For the quarter ended 30 June 2026, the company reported net income of US$2,355,556, built from US$2,519,972 of trust interest less operating costs of US$164,416. For the six months it reported net income of US$3,188,056. Working capital was US$338,659, with US$339,276 in cash. These are historical results from a company with no operating business, so they mainly reflect interest on the trust rather than performance.

Target and timetable

The prospectus says the company intends to pursue a business at the intersection of technology and health, although it had not selected a target. The deadline to complete a combination is 20 February 2028, extendable to 20 May 2028 if a definitive agreement is signed by the earlier date. Shareholders may also vote on a further extension.

Why it matters and limitations

For anyone tracking the ACAA line, the main variables are the quality and price of any eventual target, redemption levels at the shareholder vote, and the interest earned meanwhile. The quarterly report raises substantial doubt about the company's ability to continue as a going concern, a feature common among blank check companies facing a fixed deadline.

No specific target exists, and the warrants trade separately as ACAAW.

A Form 8-K and Proxy Statement Would Mark the Next Step

The documents disclose no definitive agreement date. A transaction would typically be announced in a Form 8-K, followed by a proxy statement setting out the shareholder meeting and redemption procedure.